Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Summary

This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.

Conditions

• Breast Cancer
• Metastatic Cancer

Interventions

DRUG

SHR7390

MEK1/2 inhibitor

DRUG

Famitinib

Multi-target tyrosine kinase inhibitor

DRUG

SHR3162

PARP inhibitor

DRUG

Pyrotinib

HER1 / HER2 receptor tyrosine kinase inhibitor

DRUG

Capecitabine

In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.

DRUG

SHR1210

PD-1 antibody

DRUG

Everolimus

mTOR inhibitor

DRUG

Nab paclitaxel

Albumin bound paclitaxel

DRUG

SHR2554

EZH2 inhibitor

DRUG

SHR3680

AR inhibitor

DRUG

SHR6390

CDK4/6 inhibitor

DRUG

SHR1701

anti-PD-L1/TGF-βRII bifunctional fusion protein

DRUG

SERD

Fulvestrant

DRUG

AI

aromatase inhibitor

DRUG

VEGFi

Bevacizumab

Sponsors & Collaborators

• Fudan University

  lead OTHER

Principal Investigators

• Zhi-Ming Shao · Fudan University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-01

Primary Completion

2023-05-01

Completion

2025-04-01

Countries

• China

Study Locations